An Investigation of Metabolic Risk Factors and Gut Microbiota in Unexplained Syncope.

cardiometabolic risk factors cardiovascular diseases gut microbiota unexplained syncope

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
24 Jan 2024
Historique:
received: 11 12 2023
revised: 08 01 2024
accepted: 11 01 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

The pathogenesis of many syncopal episodes remains unexplained. Intestinal dysbiosis could be involved in the pathophysiological mechanisms of syncope due to its connection with the central nervous system via the microbiota-gut-brain axis. This pilot study aimed to explore the specific cardiometabolic risk factors and gut microbiota in unexplained syncope (US), compared to other types of syncope, to assess their similarity or verify their different origins. We studied 86 participants with syncope, who were divided into four groups: an orthostatic syncope group (OH, The US group had a lower incidence of systolic hypertension at the first visit and a lower frequency of patients with nocturnal hypertension than the CS group. Compared to the OH and NMS groups, the US group had a higher incidence of carotid plaques and greater carotid intima-media thickness, respectively. The microbiota differed significantly between the US and CS groups, but not between the US group and the OH or NMS group. We observed significant differences in the gut microbiota between CS and US. Future studies are necessary to evaluate the involvement of the gut microbiota in the complex pathogenesis of syncope and whether its analysis could support the interpretation of the pathophysiological mechasnisms underlying some episodes classifiable as US.

Sections du résumé

BACKGROUND BACKGROUND
The pathogenesis of many syncopal episodes remains unexplained. Intestinal dysbiosis could be involved in the pathophysiological mechanisms of syncope due to its connection with the central nervous system via the microbiota-gut-brain axis. This pilot study aimed to explore the specific cardiometabolic risk factors and gut microbiota in unexplained syncope (US), compared to other types of syncope, to assess their similarity or verify their different origins.
METHODS METHODS
We studied 86 participants with syncope, who were divided into four groups: an orthostatic syncope group (OH,
RESULTS RESULTS
The US group had a lower incidence of systolic hypertension at the first visit and a lower frequency of patients with nocturnal hypertension than the CS group. Compared to the OH and NMS groups, the US group had a higher incidence of carotid plaques and greater carotid intima-media thickness, respectively. The microbiota differed significantly between the US and CS groups, but not between the US group and the OH or NMS group.
CONCLUSIONS CONCLUSIONS
We observed significant differences in the gut microbiota between CS and US. Future studies are necessary to evaluate the involvement of the gut microbiota in the complex pathogenesis of syncope and whether its analysis could support the interpretation of the pathophysiological mechasnisms underlying some episodes classifiable as US.

Identifiants

pubmed: 38397866
pii: biomedicines12020264
doi: 10.3390/biomedicines12020264
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of University and Research (MUR) Progetti di Ricerca di Interesse Nazionale (PRIN)
ID : 2017FM74HK
Organisme : SOPHIA Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement
ID : 875534
Organisme : PON BIO-D
ID : ARS01_00876
Organisme : MUR-PNRR M4C2I1.3 PE6 project
ID : PE00000019
Organisme : RTDa contract
ID : DM1062

Auteurs

Susanna Longo (S)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Federica Del Chierico (F)

Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.

Matteo Scanu (M)

Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.

Francesca Toto (F)

Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.

Jacopo M Legramante (JM)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Stefano Rizza (S)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Lorenza Putignani (L)

Unit of Microbiomics and Unit of Human Microbiome, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.

Massimo Federici (M)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Classifications MeSH